Safety of drotrecogin alfa (activated) in severe sepsis: Data from adult clinical trials and observational studies

Journal of Critical Care

Volumn 24, Issue 4, 2009, Pages 595-602

  Woodward, Brad ^a   Cartwright, Martina ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Activated protein C; Drotrecogin alfa (activated); Sepsis

Indexed keywords

DROTRECOGIN; ENOXAPARIN; FRESH FROZEN PLASMA; HEPARIN; PLACEBO;

BLEEDING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; HUMAN; LOW DRUG DOSE; OBSERVATIONAL STUDY; PETECHIA; REVIEW; SEPSIS; STROKE; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

AGED; CLINICAL TRIALS AS TOPIC; CRITICAL ILLNESS; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTEIN C; PROTHROMBIN TIME; RECOMBINANT PROTEINS; SEPSIS;

EID: 70449532470     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrc.2008.11.011     Document Type: Review

References (30)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 7 (2001) 1303-1310
2. Dellinger R.P. Cardiovascular management of septic shock. Crit Care Med 31 (2003) 946-955
3. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 36 (2008) 296-327
4. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709
5. Dhainaut J.F., Laterre P.F., Janes J.M., et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 29 6 (2003) 894-903
6. Ernst F.R., Viswanathan S., Vedarajan G., et al. Challenges of identification of severe sepsis in administrative data and feasibility of an alternative method. Adv Sepsis 5 (2005) 11-18
7. Eichacker P.Q., Danner R.L., Suffredini A.F., et al. Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial. Crit Care Med 33 (2005) 2426-2428
8. Gao F., Melody T., Daniels D.F., et al. The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective observational study. Crit Care 9 (2005) R764-R770
9. Williams M.D., Macias W., and Rustige J. Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions. Intensive Care Med 33 (2007) 1487-1488
10. Bertolini G., Rossi C., Anghileri A., et al. Use of drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med 33 (2007) 426-434
11. Kanji S., Perreault M.M., Chant C., et al. Evaluating the use of drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Medicine 33 (2007) 517-523
12. Aird W.C. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101 (2003) 3765-3777
13. Liaw P.C. Endogenous protein C activation in patients with severe sepsis. Crit Care Med 32 (2004) S214-S218
14. Looney M.R., and Matthay M.A. Bench-to-bedside review: the role of activated protein C in maintaining endothelial tight junction function and its relationship to organ injury. Crit Care 10 (2006) 239
15. Nick J.A., Coldren C.D., Geraci M.W., et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 104 (2004) 3878-3885
16. Nesheim M., Wang W., Boffa M., et al. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 78 (1997) 386-391
17. Esmon C.T. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 29 (2001) S48-S51
18. Macias W.L., and Nelson D.R. Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 32 (2004) S223-S228
19. Shorr A.F., Bernard G.R., Dhainaut J.F., et al. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Crit Care 10 (2006) R92
20. Macias W.L., Dhainaut J.F., Yan S.C., et al. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 72 (2002) 391-402
21. Abraham E., Laterre P.F., Garg R., et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353 (2005) 1332-1341
22. Vincent J.L., Bernard G.R., Beale R., et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33 (2005) 2266-2277
23. Levi M., Levy M., Williams M.D., et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 176 (2007) 483-490
24. Wheeler A., Steingrub J., Schmidt G.A., et al. A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial. Crit Care Med 36 (2008) 14-23
25. Safcsak K., Lipsett P., Effron M.B., et al. Safety of drotrecogin alfa (activated): results of XEUS, a prospective multicenter observational study. Chest 126 (2004) 724S
26. Dhainaut J.F., Laterre P.F., LaRosa S.P., et al. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med 31 (2003) 2291-2301
27. Barie P.S., Williams M.D., McCollam J.S., et al. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 188 (2004) 212-220
28. Payen D., Sablotzki A., Barie P.S., et al. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort. Surgery 140 (2006) 726-739
29. Barie P.S., Hydo L.J., Shou J., et al. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis. Surg Infect 7 (2006) S77-S80
30. Dhainaut J.F., Yan S.B., Joyce D.E., et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2 (2004) 1924-1933